On Sept. 13, 2021, Twist Bioscience announced and Adicet Bio announced a collaboration to accelerate the discovery of gamma delta T cell therapies against five undisclosed targets. The companies planned to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens.